U.S. Markets closed

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
46.30-0.07 (-0.15%)
At close: 4:00PM EDT
People also watch
IMGNBMRNINCYALNYCLDX
  • M
    Maurizio
    Maurizio
    Have we finally bottomed???!!!
  • T
    Trent
    Trent
    52 week low on recent submission to the FDA with expedited decision ? Strange.
  • A
    Anonymous
    Anonymous
    Over 200k shares awarded to executive staff at this point in time (vesting over 4 years) would seem to be bullish timing.
    Paladin
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    Looks like Bakers may be buying. Just a hunch. We will see soon. Someone is jumping in though.
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    Bakers silent since November. Hope they don't add to position. Thinking there setting up for sale or they would be pouncing at a mid 40 price. Especially since they pounced at mid 50's in November. 46 Friday and then mid 90's takeout over one of these weekends. Cmon Felix. Let the baby rip!
  • D
    Diane
    Diane
    Any stock that tanks 30 bucks is due for a rebound. BUY NOW.
  • f
    flickr
    flickr

    Don't forget this could be SGEN at ASH.

    Roche Holding AG RHHBY -0.08% shares jumped 6.5% on a single day in early March when the drugmaker said its new breast-cancer treatment, Perjeta, helped prolong average patient survival in a clinical study.

    But the stock gave up nearly all those gains three months later, when the Swiss company disclosed full details of the trial at a medical conference. The study, dubbed Aphinity, showed what some doctors said was only a marginal benefit for Perjeta, and investors, initially hopeful of a big sales boost for the drug, lowered their expectations.

    https://www.wsj.com/articles/some-investors-feel-burned-by-drugmakers-clinical-trial-reports-1502712000?tesla=y&mod=e2tw

    Some Investors Feel Burned by Drugmakers’ Clinical-Trial Reports
    Roche angered some U.S. shareholders when a medical presentation about a clinical-trial involving the cancer drug Perjeta didn’t bear out the drugmaker’s earlier upbeat disclosures.
    www.wsj.com
  • c
    chrag
    chrag
    10 dollar is where this belongs
    Look what Baker Brothers did to Immunogen ( IMGN)...pumped it to 17 with half-a#$ phase 2 data on mirvetuximab and is now a 6 dollar stock.
  • D
    Diane
    Diane
    AQXP-Told ya. Baker's controlling both SGEN and AQXP.
  • r
    ron
    ron
    Bakers selling any of this crud?
  • B
    BillB
    BillB
    Any thoughts out there on the purchase of the Bothall manufacturing facility? Will this allow for faster rollout of any new drugs? Will there be any opportunities to use these facilities to capture additional revenue by producing other companies medicines? Thanks in advance to any knowledgeable posters. These boards used to provide so much good info--since Yahoo revised them, not much of value hits. I did like your previous post Anonymous--it was very thoughtful and well supported factually. Thank you!!
  • f
    flickr
    flickr
    Sold it all today. It's a shame but 50.00 was my trigger. Technical support levels now are around 45 and if that doesn't hold you are looking at 35.00. My biggest fear is ASH. The press release on Echelon 1 mentions the 82 % PFS but states nothing about pulmonary tox. Pulmonary tox is associated with Adcetris (black box warning, and the argument for E1 financial success is that removing Bleomycin would get rid of it in 11 % of patients. However, it's unknown if AVD Adcetris combo decreases p. tox. if not uh hoh.
  • m
    michael
    michael
    When it is all said and done, blowing the gift that was the IMMU deal will loom large in the future of SGEN. IMMU 132 is potentially the multibillion dollar therapy that you all have been praying for. And it was right there...
  • .
    .
    .
    Is this turd rocket seriously down to $49.22? Remember the good old days when it was $68? Will this POS ever stop bleeding?
  • r
    redhot47fla
    redhot47fla
    From our misery-loves-company file comes this observation from someone on Twitter: "Bakers position only down $1.2 billion since hitting 52 week highs."
  • r
    ron
    ron
    Hope to see a pop, so I can a chunk. This a roller coaster without thrills.
  • a
    atpl1959
    atpl1959
    I thought it was an interesting and intentional observation regarding the 92% CR rate in the lead in trial with the 82% rate in E1. I've been wondering if the good, but somewhat lower than hoped CR rate may have been somewhat influenced by the worldwide nature of the study and perhaps lass stringent adherence to treatment protocol as would be expected in the top institution and top Drs. that performed the lead in trial. I wonder if data at ASH will be broken down somewhat geographically that may have influenced the overall results.
  • A
    Anonymous
    Anonymous
    The following is a list of hare brained decision by SGEN management over the past 1.5 years that have destroyed $ 3 billions of shareholder value:
    1) Delaying application for FDA approval after Alcanza ended by 6 months to include investigator sponsored data to get a slightly more comprehensive label thus preventing at least 6 months additional revenues from the Alcanza only label expansion from being captured.
    2) Decision to buy IMMU P2 drug for $300K upfront when no one else would and overlook the fact that VenBio would sue with a better than 50/50 chance of getting the deal voided
    3) Decide to proceed with multiple CD33 P3 trials bypassing P2 and by doing so miss the opportunity to learn about the weakening of the patients' immune system which facilitates infections. Irrespective of P2, bright bioscientists should have suspected this occurence because weakening the immune system always facilitates an increase in infections. This decision caused squandering of funds to initiate and run the trials which then had to be stopped incomplete. In addition of the waste of money, this event is at the very least damaging the reputation of the CD33 drug going forward and could very well have killed it.
    4) Releasing underwhelming raw results for E1 without proposing reasons for why it may be underwhelming at first and not revealing any additional results from analysis of the data during the CC a month later because it needs to remain secret for an additional 5 months so that it can be disclosed at ASH with fanfare.
    6) Announcing that they are acquiring a new building and staff to produce their own antibodys a day after the underwhelming CC. Perhaps they thought that shareholders should be excited for the prospect of them burning money even faster now that a second potential drug is several years away after the failure of CD33.
    Kool
  • a
    atpl1959
    atpl1959
    From my perspective this CC was much more detailed and very upbeat. A far cry from the E1 results CC where it sounded like Clay was up all night and ill prepared.